Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.75 SEK | -0.53% | +0.81% | +39.41% |
03-13 | CombiGene's Epilepsy Project CG01 Receives Patent in Two New Countries | CI |
02-21 | Orphazyme A/S acquired an additional unknown minority stake in CombiGene AB (OM:COMBI). | CI |
Sales 2021 | 91.15M 8.35M 666M | Sales 2022 | 28.73M 2.63M 210M | Capitalization | 181M 16.57M 1.32B |
---|---|---|---|---|---|
Net income 2021 | 21M 1.92M 154M | Net income 2022 | -6M -550K -43.86M | EV / Sales 2021 | 0.98 x |
Net cash position 2021 | 137M 12.53M 1B | Net cash position 2022 | 132M 12.07M 963M | EV / Sales 2022 | 1.71 x |
P/E ratio 2021 |
9.42
x | P/E ratio 2022 |
-29.4
x | Employees | 11 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 69.54% |
1 day | -0.53% | ||
1 week | +0.81% | ||
Current month | +5.04% | ||
3 months | +22.95% | ||
6 months | +50.91% | ||
Current year | +39.41% |
Managers | Title | Age | Since |
---|---|---|---|
Peter Ekolind
CEO | Chief Executive Officer | 60 | 26/09/22 |
Louise Aspenberg
DFI | Director of Finance/CFO | 48 | 11/10/20 |
Daniela Morath
ADM | Chief Administrative Officer | 44 | 31/12/17 |
Members of the board | Title | Age | Since |
---|---|---|---|
Gunilla Lundmark
BRD | Director/Board Member | 61 | 31/12/20 |
Director/Board Member | 59 | 31/12/19 | |
Director/Board Member | 54 | 30/09/14 |
Date | Price | Change | Volume |
---|---|---|---|
29/04/24 | 3.75 | -0.53% | 5 590 |
26/04/24 | 3.77 | +0.27% | 5,340 |
25/04/24 | 3.76 | -1.05% | 15,148 |
24/04/24 | 3.8 | 0.00% | 2,435 |
23/04/24 | 3.8 | +2.15% | 9,353 |
Delayed Quote Nasdaq Stockholm, April 29, 2024 at 09:41 am
More quotes1st Jan change | Capi. | |
---|---|---|
+39.41% | 6.81M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+0.79% | 22.15B | |
-17.37% | 21.02B | |
-7.98% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- COMBI Stock